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 Graphical abstract 
 
 
Highlights 
 VEGF was biomimetically conjugated onto PLGA NF scaffolds through heparin 
 The grafting technique fulfilled the sustained release and bioactivity of VEGF 
 Conjugated VEGF and co-culture with HUVECs regulated MSCs’ activities 
 Osteogenesis and angiogenesis differentiation of MSCs were specie dependent 
 
Abstract 
 
The purpose of this work was to investigate if the biomimetically conjugated VEGF and 
HUVECs co-culture could modulate the osteogenic and angiogenic differentiation of MSCs 
derived from rat and human bone marrow (rMSCs and hMSCs). After treated by ammonia 
plasma, Poly(lactic-co-glycolic acid) (PLGA) electrospun nanofibers were immobilized with 
VEGF through heparin to fulfil the sustained release. The proliferation capacity of rMSCs and 
hMSCs on neat PLGA nanofibers (NF) and VEGF immobilized NF (NF-VEGF) surfaces 
were assessed by CCK-8 and compared when MSCs were mono-cultured and co-cultured 
with HUVECs. The effect of VEGF and HUVECs co-culturing on osteogenic and angiogenic 
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 differentiation of rMSCs and hMSCs were investigated by calcium deposits and CD31 
expression on NF and NF-VEGF surfaces. The results indicated that VEGF has been 
biomimetically immobilized onto PLGA nanofibers surface and kept sustained release 
successfully. The CD31 staining results showed that both VEGF and HUVEC co-culture 
could enhance the angiogenesis of rMSCs and hMSCs. However, the proliferation and 
osteogenic differentiation of MSCs when cultured with VEGF and HUVECs showed a 
species dependent response. Taken together, VEGF immobilization and co-culture with 
HUVECs promoted angiogenesis of MSCs, indicating a good strategy for vascularization in 
bone tissue engineering.  
 
Keywords: MSCs, HUVECs, co-culture, osteogenic, angiogenic 
 
Introduction 
 
The main challenge for bone tissue engineering is to integrate the generated new bones 
with host to perform their function [1]. Many scaffolds have been developed and employed to 
induce bone formation for long bone defect repair. One limitation of these studies is the low 
diffusion of oxygen and nutrition in the engineered products due to lack of blood vessel 
networks [2, 3]. Current tissue engineering strategies for vascularization of bone scaffolds are 
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 growth factors delivering and endothelial cells introducing to fabricate vascularized tissue 
engineering bone [4]. 
 
Vascular endothelial growth factor (VEGF), originally known as vascular permeability 
factor (VPF), is one of the most important proangiogenic factors that can stimulate new blood 
vessels formation during embryonic development and new vessels regeneration after injury [5, 
6]. Several signaling pathways were activated by the binding of VEGF with its receptors, 
leading to increased survival, proliferation, penetration, and migration of cells [7], which can 
help blood vessel’s rebuilding after injury. Therefore, VEGF is one of the most commonly 
used growth factor for vascularization in bone tissue engineering [8, 9]. While the half-life of 
VEGF is very short, only 6-8 hours. Stabilization of VEGF and achieving its sustained 
releasing are required for in vitro and in vivo application [4]. 
Encapsulation of growth factors by hydrogel and biodegradable polymers has been 
employed to realize their sustained releasing. Zhang et al had injected silk hydrogel 
encapsulated with VEGF and bone morphogenetic protein-2 (BMP-2) to the rabbit maxillary 
sinus floor to promote angiogenesis and new bone formation [10]. Degradable poly (DL-lactic 
acid) scaffolds encapsulated with VEGF and seeded with human bone marrow stromal cells  
exhibited increased bone volume and blood vessel formation following implantation in a 
mouse femur segmental defect [11]. Besides depending on the degradation of scaffolds, 
controlled delivery of growth factors can accomplished by covalent and affinity binding them 
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 to scaffold’s surface [4]. Polydopamine has been deposited onto the surface of poly(L-lactide-
co-ε-caprolactone) to mediate the immobilization of VEGF for accelerating endothelialization 
of vascular grafts [12]. Previous studies have bonded a series of proteins through heparin, 
which can preserve the biological activity of proteins. Heparin, as part of proteoglycans, is 
ubiquitously present in the cell surface and extracellular matrices of mammalian cells. It has 
been demonstrated that heparin not only bind VEGF directly but also enhance VEGF binding 
to VEGF receptor 2 as a complex, ultimately controlling VEGF activity [13]. Heparin also 
provide an abundance of hydroxyl and carboxylic acid groups allowing it to be easily 
modified with reactive group of scaffolds [14, 15].  
 
In addition to growth factor stimulation, another approach to achieve vascularization in 
bone tissue engineering is the recruitment of stem cells, endothelial cells and other cells to 
develop capillary and vessels. Mesenchymal stem cells (MSCs), derived from bone marrow, 
adipose tissue, umbilical cord et al, have low immunogenic property and multi-differentiation 
potential and were widely used in tissue engineering of bone, nerve, tendon and cartilage [16]. 
The immunosuppressive properties of MSCs, performing through modulating T-cell functions, 
may have therapeutic benefit for the transplantation of scaffolds with cells [16]. It has been 
demonstrated that MSCs co-cultured with human umbilical vein endothelial cells (HUVECs) 
achieved excellent osteogenic and angiogenic capability in vivo [17]. Ma et al. investigated the 
angiogenic capacity of MSCs co-culturing with HUVECs when implanted into mice and 
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 evaluated the different healing effects of MSCs when derived from human bone marrow and 
adipose [18]. However there was no report whether the effect from MSCs when co-cultured 
with HUVECs is species dependent. 
 
As an FDA-approved polymer, poly(D, L-lactic-co-glycolic acid) (PLGA) with adjustable 
degradation rate was used widely in tissue engineering to fabricate into scaffolds [19]. 
Electrospining PLGA into nanofibraous scaffolds has an advantage to biomimic native 
extracellular matrix. However, like most polyester polymers, PLGA is a hydrophobic polymer 
with no reactive group and recognition sites for cell attachment. Therefore, it is important to 
modify PLGA surface and introduce active biomolecules onto PLGA scaffolds to promote 
specific cell adhesion, proliferation and differentiation. 
 
In this study, we developed a new technique to immobilize VEGF to synthetic nanofibrous 
scaffolds and evaluate its effects on osteogenic and angiogenic capacity of MSCs and 
HUVECs co-culture models. The MSCs from rat and human were used to study the species 
dependency. We hypothesize that biomimetically incorporation of VEGF can maximize its 
activities for sustained work period, and VEGF and co-culture conditions on osteogenisis and 
angiogenisis are cell species dependent. 
 
Materials and Methods 
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Electrospun PLGA nanofibrous scaffolds 
Poly(lactic-co-glycolic acid) (PLGA) nanofibrous scaffolds were fabricated by electrospun 
technique as described in our previous study [20]. Briefly, 3% PLGA (w/v) electrospinning 
solution was obtained by dissolving PLGA granule (200 K, Purac, Netherlands) in chloroform 
and N, N-dimethylformamide (3:1 v/v). The solution was delivered by a syringe at 1.5 mLh-1. 
The distance between the syringe needle (positive electrode) and the collector (negative 
electrode) was 25 cm and the voltage was set as 15 kV. The formed PLGA nanofibrous (NF) 
scaffolds were stabilized on round coverslips and kept in vacuum oven overnight to evaporate 
the residue solvent and were sterile by immersing in 70% ethanol for 30 minutes. Scanning 
electron microscope (SEM, ultra plus Zeiss, Germany) was used to observe morphology of 
PLGA nanofibers. 
 
Preparation of VEGF-modified PLGA electrospun scaffolds 
VEGF was immobilized to PLGA NF by a two-step process as illustrated in Figure 1. The 
first process step was introduction of amine groups to the surface of PLGA through ammonia 
plasma treatment. In the second step of the process, heparin was grafted to the amine groups 
on the NF surface covalently, then VEGF was immobilized to the PLGA NF scaffolds 
through affinity binding. 
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 Ammonia plasma treatment:  Plasma treatment of PLGA NF scaffolds to graft amine 
groups was performed in a glow discharge stainless steel reactor (Diener electronic, Plasma-
Surface-Technology, Germany). Scaffolds were put into the chamber and the reactor was 
evacuated to 21 mbar, followed by pumping ammonia gas and maintenance at 50 mbar. 
Plasma treatment was lasting for 5 minutes. The treated scaffolds were denoted as NF-NH2. 
 
Heparin crosslink through EDC/NHS:  Heparin modification was accomplished by using 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (Sulfo-NHS) as crosslink agents following an established protocol 
[21]. Briefly, EDC, sulfo-NHS, and heparin solution were added into 2-(morpholino) 
ethanesulfonic acid buffer with the final concentration of 2 mM, 5 mM, and 1 mgmL-1 
respectively and mixed for 15 minutes at room temperature to active the carboxylic group of 
heparin. β-mercaptoethanol was added with the final concentration of 20 mM to inactivate the 
EDC, after which increased the system pH to 7.0 by adding concentrated PBS. 500 L of the 
mixed solution was added to NF-NH2 scaffolds with the surface area of 0.8 cm
2 for 2 hour 
reacting at room temperature. Any remaining heparin was removed by washing the scaffolds 
with PBS for three times. The amount of heparin on the surface of PLGA NF scaffolds was 
measured by Toluidine Blue assay [22].  
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 VEGF modification: 100 ngmL-1 of VEGF (VEGF165, PeproTech, UK) solution in 1% 
BSA was added to PLGA NF, NF-NH2, and NF-Heparin scaffolds and incubated overnight at 
4°C. All scaffolds were washed with PBS for three times after the reaction.  
To quantify the amounts of immobilized VEGF on scaffolds, the concentration of 
remaining VEGF solution after immobilization reaction was measured by the ELISA kit 
following the recommendation of the manufacturer (Elabscience, China) [12].  
To visualize the immobilized VEGF on scaffolds, immunofluorecence staining of the 
scaffolds was undertaken [23]. After immersed in 100 ng/mL VEGF solution at 4 °C overnight, 
NF, NF-NH2, and NF-Heparin scaffolds were stained using rabbit anti-human VEGF primary 
antibody (1:200, Santa Cruz, USA) and Alex488-conjugated mouse anti-rabbit secondary 
antibody (1:200, Invitrogen, USA). Fluorescence microscope (Leica, Gemany) with fixed 
imaging parameters were used across all samples.  
To test the sustained releasing of VEGF, PLGA NF, NF-NH2, NF-VEGF scaffolds were 
incubated in PBS at 37 °C up to 31 days. At predetermined time points, 100 μL releasing 
VEGF solution was collected and analyzed by a modified ELISA assay (ELISA kit, 
PeproTech, USA) according to the manufacturer’s instructions. 
 
Characterization of surface wettability 
Water contact angles were measured to determine the wettability of PLGA NF, NF-NH2, 
and NF-VEGF scaffolds. Three samples of each group were measured by dropping 4 µL 
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 dH2O onto the surface and the droplet images were taken in 3 seconds by an Olympus camera. 
ImageJ software was used to analyze the images to obtain the contact angles of samples. 
 
Effects of surface modification on the viability of cells 
MSCs, isolated from Sprague-Dawley rats’ bone marrow as described in our previous study 
[20], were cultured in α-MEM (Biosera, UK) supplemented with 10% FBS (Biosera, UK) and 
1% Penicillin/streptomycin (A+A, Lonza, UK) under 37 °C and 5% CO2. Ten thousand 
passage 2 MSCs were seeded onto each scaffold of PLGA NF, NF-NH2, NF-Heparin and NF-
VEGF. The viability of MSCs on the surface of each group at day 5 culture was determined 
by live and dead staining assay (Cellstain double staining kit, Sigma, USA). Confocal 
microscopy (Olympus, USA) with 490 nm and 535 nm excitation was used to observe the cell 
survival rate. 
 
Proliferation study of HUVECs and MSCs co-culture  
Human MSCs were isolated from human bone marrow mononuclear cells (Lonza, UK) by 
culturing in flasks coated with fibronectin (R&D System, UK) in low glucose DMEM 
(Biosera, UK) supplemented with 10% FBS and 1% A+A under 37 °C and 5% CO2. Passage 
3-5 of human MSCs were used in this study. 
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 In the study of MSCs co-cultured with endothelial cells, MSCs derived from rats and 
human bone marrow (rMSCs and hMSCs) were used. HUVECs were purchased from GIBCO 
(Life Technologies, USA) and cultured in M200 media with low serum growth supplementary 
(LSGS, GIBCO, USA). HUVECs and r/hMSCs were co-cultured (rMIX and hMIX) on the 
surfaces of PLGA NF and NF-VEGF at a ratio of 1:9 with the total loading density of 2×104 
cm-2 in a mixed medium by 1:1 α-MEM/M200 (MIX media). As control groups, r/hMSCs 
were mono-cultured in the same condition respectively. 
 
Cell proliferation was tested by Cell Counting Kit-8 (CCK-8, Dojindo, Japan) as described 
in our previous study [20]. Briefly, at 1, 4, and 7 days after cell seeding, 220 μL of CCK-8 
solutions at a dilution of 1:10 with MIX media were added to each sample and cultured at 
37 °C with 5% CO2. Two hours later, 100 μL of media were transferred to 96-well plate to 
measure absorption value at a wavelength of 450 nm using a microplate reader (Symergy HT, 
BioTek, USA). 
 
Differentiation study of co-cultured HUVECs and MSCs 
After co-cultured in MIX media for 1 week, rMSCs, rMIX, hMSCs, and hMIX on scaffolds 
of PLGA NF and NF-VEGF were changed into osteogenic condition, in which contained 50% 
M200 (supplemented with LSGS) and 50% osteogenic media (low glucose DMEM 
supplemented with 10% FBS, 1% A+A, 10 mmol/L glycerol phosphate, 10 nmolL-1 
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 dexamethasone, 50 μmolL-1 L-ascorbic acid, 300 mgL-1 L-glutamine and 10 nmolL-1 1α, 25-
dihydroxyvitamin D3 (Sigma-Aldrich, USA)). The media were changed every three days. 
 
Alizarin Red staining: In order to stain the calcium mineralization on NF and NF-VEGF 
scaffolds, samples with rMSCs, rMIX, hMSCs, and hMIX were fixed with 70% ethanol for 1 
hour at room temperature after cultured for 28 days. After washed once with tape water, 
samples were immersed into 40 mM Alizarin red S (ARS, Sigma, USA) for 20 min and then 
washed five times with tape water. All samples were observed under bright field microscopy. 
To quantify the calcium mineralization, ImageJ was used to analyze the percentage of stained 
area. 
 
SEM-EDX analysis: The calcuim element distribution within the cells was analyzed using 
SEM in combination with energy dispersive X-ray analysis (SEM-EDX) (TM-3000, Hitachi, 
Japan). The elemental distribution of Calcium was mapped and analyzed.  
 
ALP staining: Alkaline phosphatase (ALP) staining was conducted using an ALP kit 
(Millipore, UK). All samples were fixed with 4% paraformaldehyde for 2 minutes and stained 
following the kit instructions. The staining samples were observed under microscope. ImageJ 
was used to quantify the percentage of ALP stained area.  
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 CD31 immunofluorescence staining: The effect of NF-VEGF scaffolds on CD31, the 
specific marker of HUVECs, expression, co-cultured HUVECs/r/hMSCs were investigated by 
immunofluorescence staining at day 21 culture. All samples were rinsed twice with PBS and 
fixed in 4% of PFA for 30 minutes at room temperature. The fixed samples were immersed in 
1% bovine serum albumin (BSA)/PBS blocking buffer for 1 hour at 37 °C, and then were 
incubated with rabbit anti-rat CD31 primary antibody (1:200, Santa Cruz, UK) overnight at 
4 °C. Then the samples were incubated in anti-rabbit secondary antibody TRITC (1:200, 
Santa Cruz, UK) for 2 hours at 37 °C. The samples were counterstained with DAPI (Abcam, 
USA) and visualized with a confocal microscopy (Olympus, USA). To quantify the 
angiogenesis, ImageJ was used to analyze the percentage of CD31 stained area. 
 
Statistical analysis 
All quantitative results are expressed as mean ± standard deviation. N = 3 were for treated 
groups. Statistical analysis was carried out using one-way ANOVA and t-test for each two 
group comparisons to determine significance. A value of P<0.05 was considered to be 
statistically significant. 
 
Results 
 
Biomimetically conjugation of VEGF on PLGA NF scaffolds 
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 PLGA electrospinning fibers: Electrospinning technique produced PLGA nonwoven 
nanofibers with 588.9 ± 110.3 nm in diameter. SEM image in Figure 2A shows the 
morphology of PLGA NF and the inset shows the diameter distribution of nanofibers. The 
PLGA NF scaffolds exhibited a structure similar to extracellular matrix with pore structure 
and fibers with diameter ranged from 350 nm to 960 nm. 
 
Heparin modification: PLGA NF modification was performed according to the procedure 
shown in Figure 1. Amine groups were grafted to NF surface by ammonia plasma treatment, 
after which heparin was conjugated using EDC/Sulfo-NHS which can activate carboxylic acid 
groups of heparin. According to the toluidine blue assay results (Figure 2B), 1.73 ± 0.06 
μgcm-2 heparin was conjugated to NF-NH2 scaffolds, indicating that the heparin modification 
of PLGA nanofibrous scaffolds was successful. 
 
VEGF immobilization and releasing: Biomimetically conjugation of VEGF was 
accomplished through affinity binding with heparin. Figure 2C shows the release kinetics of 
VEGF from the electrospun PLGA NF with or without heparin conjugation. When VEGF was 
reacted with NF scaffolds without any treatment, the resulted scaffolds showed a low and 
abrupt initial burst release over the first 3 days of study. Almost no more additional release of 
VEGF was seen over the remaining experimental days. When VEGF was reacted with NF-
NH2 scaffolds without of heparin conjugated, the resulted scaffolds showed released VEGF to 
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 5 days, after which no more releasing was detected. In contrast, a sustained release of VEGF 
in NF-heparin scaffolds was observed up to 31 days. The immunofluorecence staining and 
ELISA results of remaining reaction solutions indicated that VEGF grafting was siginificantly 
more efficient on NF-Heparin surface than the NF and NF-NH2 surface (Figure 2E-H). 
 
Contact angle: The surfaces wettability of modified PLGA substrates were evaluated by 
measuring contact angle according to our previous study [24]. The water contact angle on the 
ammonia plasma treated PLGA NF was dramatically decreased from 84.08 ± 1.30 to 39.23 ± 
1.09 (Figure 2D). In addition, VEGF modified PLGA NF displayed the lowest contact angle 
(21.94 ± 3.81). The water droplet images on NF, NF-NH2, and NF-VEGF scaffolds surfaces 
are presented in Figure 2D. 
 
Biocompatibility of NF modification: Figure 3 shows the cell viability on the surfaces of NF, 
NF-NH2, NF-Heparin, and NF-VEGF after seeded 5 days. It can be seen that most of MSCs 
attaching to PLGA NF were alive (green staining), while a few of them showed round shape 
and red fluorescence (dead cells) (Figure 3A1-A4). After ammonia plasma treatment and 
heparin conjugation, cell biocompatibility of PLGA NF was improved and the number of 
round and dead cells decreased (Figure 3B1-B4, C1-C4). On the surface of NF-VEGF, the 
highest number of live and well spread cells was observed. 
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 Species dependent response on proliferation and osteogenesis 
Proliferation of r/hMSCs: Figure 4A, B, and C showed the morphology of rMSCs, hMSCs, 
and HUVECs at day 3 of passage 2. Figure 4D and E showed the proliferation of rMSCs, 
rMIX, hMSCs, and hMIX after seeded on the surfaces of NF and NF-VEGF for 1, 3 (4), and 7 
days. From Figure 4D, it can be found that VEGF modification can promote cell proliferation 
both in rMSCs and rMIX groups. However, when cultured on neat NF scaffolds, rMSCs grew 
much slower than that on VEGF modified NF, neither mono-cultured nor co-cultured with 
HUVECs. Figure 4E shows that both hMIX and hMSCs proliferated along with cultured time, 
while hMIX growth was faster than hMSCs on both NF and NF-VEGF surfaces. There was 
no difference of cell proliferation between each two types of surface when seeded with 
hMSCs or hMIX. 
 
Osteogenesis of r/hMSCs: The osteogenesis capacity of MSCs derived from rats or human 
marrow seeded on PLGA NF and NF-VEGF scaffolds were evaluated by ALP at day 7 and 
calcium deposit staining with Alizarin Red S and SEM-EDX after 4 weeks of culture. In 
Figure 5, calcium deposition staining (red area) can be found on both types of surfaces (NF 
and NF-VEGF) seeding with rMSCs or rMIX under the osteogenic media (Figure 5A-D). Co-
cultured with HUVECs, rMSCs showed higher level of calcium deposition on both NF and 
NF-VEGF surfaces (Figure 5C-D). Furthermore, it can be found that in compared with VEGF 
modified surface, rat MSC mono-culture had higher calcium deposition on NF surface (Figure 
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 5A and B). The area of ARS staining regions was quantified as shown in Figure 5E. The co-
cultured samples showed much higher level of calcium deposition compared with rMSCs 
mono-culture (P<0.01). The calcium element distribution results on NF and NF-VEGF 
surfaces detected by SEM-EDX analysis further confirmed the osteogenic differentiation of 
rMIX (Figure S1). 
 
Figure 6 shows ARS staining on PLGA NF and NF-VEGF surfaces when seeding human 
MSCs for both mono- and co-culture (hMSCs and hMIX) under osteogenic media (Figure 
6A-D). It can be found that when cultured on NF, both hMSCs and hMIX showed higher 
osteogenesis level in comparison of that on NF-VEGF surface. However, co-cultured with 
HUVECs didn’t enhanced the osteogenesis level of hMSCs no matter what type of surface is. 
The calcium deposition was quantified by analysis of ARS staining images (Figure 6E). It was 
revealed that the effect of VEGF on osteogenesis of hMSCs and hMIX were not significantly 
different and co-culture also had no significant effects on hMSCs’ osteogenic differentiation 
(P>0.05). 
 
ALP expression showed strong species and surface chemistry dependent pattern (Figure 
S2). In general, no VEGF treated surface exhibited higher ALP expression for both rat and 
human MSC samples than NF-VEGF surface and co-culture of rat MSC with HUVECs 
demonstrated the highest APL expression. 
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Enhancement of angiogenesis by the immobilized VEGF and co-culture 
VEGF effects on angiogenesis: The angiogenesis capacity of MSCs derived from rats or 
human bone marrow seeded on PLGA NF and NF-VEGF scaffolds were evaluated by CD31 
immunofluorescence staining after 3 weeks of culture. CD31 expression of cells on PLGA NF 
and NF-VEGF surfaces were recorded by confocal microscopy. The fluorescence images of 
the CD31 expression were quantified as shown in Figure 7A1-D2. To eliminate the effects of 
cell number, the expression of CD31 was normalized by nuclei stained by DAPI. As shown in 
Figure 7A1 and B1, C1 and D1, VEGF immobilized on NF enhanced the expression of CD31 
in rat MSCs mono- and co-culture (rMSCs and rMIX) in comparison to on PLGA NF 
surfaces. Interestingly, rMIX cultured on NF-VEGF scaffolds formed cell aggregates, which 
never showed when rMSCs seeded alone. Figure 7E showed the quantification of CD31 
staining area normalized by nucleus according to the fluorescence images in Figure 7A-D. 
 
Similarly CD31 expression of hMSCs and hMIX culture on the surfaces of NF-VEGF was 
significantly enhanced in comparison to on PLGA NF surface as shown in Figure 8. 
 
Co-culture enhanced angiogenesis: It can be seen from Figure 7 that rMSCs and HUVECs 
co-cultured groups had higher CD31 expression than rMSCs mono-cultured groups on both 
PLGA NF and NF-VEGF surfaces. From Figure 7E we can found that rMIX cultured on NF-
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 VEGF group had the highest CD31 expression than other groups, which indicated the 
synergistic effects of co-culture and VEGF on the angiogenesis of rMSCs. Comparing the 
CD31 staining area of rMSCs on NF-VEGF and rMIX on NF, we noticed that the two groups 
had similar CD31 expression level (P>0.05), indicating the analogous effects of VEGF and 
HUVECs on the angiogenic differentiation of rMSCs. 
 
In Figure 8E, it showed that hMIX seeded on PLGA NF surface (Figure 8C) had higher 
CD31 expression than that hMSCs on NF surface (Figure 8A). However, comparing hMIX on 
NF-VEGF (Figure 8D) with hMIX on NF (Figure 8C) and hMSCs on NF-VEGF (Figure 8B), 
we noticed that the synergistic effects of co-culture and VEGF on the angiogenesis of hMSCs 
was not as obvious as rMSCs. 
 
Discussion 
 
One important role of scaffolds in tissue engineering is to serve as a vehicle for delivery of 
growth factors [25]. VEGF, one of the most important growth factors in angiogenesis, not only 
has effects on vascular invasion, but also can promote bone regeneration [7]. Therefore, 
various techniques have been employed to immobilize VEGF to bioactive and biomimetic 
polymer scaffolds, such as physical encapsulation, covalent binding, and affinity binding. 
Among these methods, affinity binding can mimic interactions between growth factors and 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 natural extracellular matrix and avoid the rapid degradation, which facilitated sustained 
releasing of growth factors [4]. Thus, in this study, VEGF was immobilized to PLGA NF 
scaffolds through heparin which has high affinity binding towards VEGF and can preserve the 
biological activity of VEGF [26]. Given the deficiency of amine groups reacting with heparin, 
PLGA NF were treated with ammonia plasma treatment to obtain NF-NH2 scaffolds and then 
heparin molecules were covalently attached to NF-NH2 surface via EDC/Sulfo-NHS. The 
contact angle changes, Toluidine Blue assay results, and the in vitro VEGF release kinetics all 
indicated that amine group, heparin, and VEGF have incorporated successfully to the surface 
of PLGA NF covalently and biologically. The release kinetics also showed that we 
accomplished sustained releasing of VEGF through affinity binding to heparin.  
 
Live and dead staining results indicated the improved biocompatibility of NF after 
modified by plasma treatment, heparin and VEGF grafting. It has been demonstrated that 
ammonia plasma treatment can introduce amine groups to surface of polymer scaffolds and 
improve their cell compatibility [24]. While the anti-proliferation effect of heparin on vascular 
smooth muscle cells (SMCs) has been reported in previous research, which was in conflict 
with our results that heparin modified surface had better cell viability compared with neat NF 
surface. We speculated that this contradiction might come from the heparin supplementary 
methods in our study, in which rMSCs and conjugated heparin were used instead of SMCs 
and free heparin in other study [14]. 
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It has been previously demonstrated that hMSCs co-cultured with HUVECs can support 
cell proliferation because of the cross talk between hMSCs and HUVECs [27]. Related findings 
were reported by Ma and colleagues who found that cell proliferation increased when 
HUVECs co-cultured with both human bone marrow derived MSCs and human adipose tissue 
derived MSCs [18]. Our study was consistent to that study and showed that HUVECs can 
enhance proliferation of hMSCs on both NF and NF-VEGF surfaces, while VEGF can 
promote the attachment and proliferation of rMSCs and rMIX. Both rMSCs and rMIX on NF 
showed lower attachment level compared with that on modified NF surfaces, which was in 
compliance with the live and dead staining results.  
 
Co-culture of vascular endothelial cells and stem cells is one of the promising strategies to 
enhance vascularization in bone tissue engineering [28]. HUVECs and bone marrow derived 
MSCs were the most commonly used cell types [29]. In this study, we co-cultured HUVECs 
with MSCs from different species to evaluate their osteogenic and angiogenic differentiation 
efficiency on surface modified NF scaffolds. The differentiation results showed that 
angiogenesis was enhanced in both co-culture groups, rMIX and hMIX, which can be 
explained by the angiogenic differentiation of MSCs through the cross-talk between MSCs 
and HUVECs. Previous researchers investigated the in vivo and in vitro angiogenic capacity 
of MSCs-HUVECs and found that co-culture can enhance vascularization [30]. We noticed that 
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 the CD31 expression of hMIX was much higher than that of rMIX on the scaffold surfaces, 
indicating that MSCs from different species could have diverse reactions when co-cultured 
with HUVECs. This speculation was confirmed by the supplementary evidence from 
osteogenic results, from which we found that rMIX had higher level of osteogenesis 
compared with rMSCs monoculture while there was no difference between hMSCs and hMIX. 
Song and colleagues found that endothelial progenitor cells (EPCs) and bone marrow stem 
cells (BMSCs) co-cultured together can promote angiogenesis but retard terminal 
differentiation of osteoblasts in bone regeneration by up-regulating Id1 [31]. However, most 
HUVEC-hMSC co-cultured experiments supported that co-culture can enhance osteogenesis 
than monoculture [17]. The mechanism needs further investigation. 
 
Another interesting result conflicted with previous research in this study was that VEGF 
modified NF scaffolds cannot promote osteogenic differentiation of MSCs whether from rat 
bone marrow or from human bone marrow. Villars and colleagues noticed that early 
osteoblastic marker (ALP) levels increased when human bone marrow stromal cells were co-
cultured with HUVEC in direct contact. However, unlike previous studies, they also did not 
find that VEGF increased these processes [32]. Given the high expression of CD31 in NF-
VEGF groups, we speculated that this phenomenon can be explained by the competition 
reaction of MSCs to the osteogenic and angiogenic mixture media. On NF-VEGF surface, 
VEGF triggered the angiogenic signal pathways inside MSCs and angiogenic media induced 
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 following angiogenesis procedure. There is an essential balance between angiogenic and 
osteogenic growth factors during bone healing and excessive concentration of VEGF may 
favorite endothelial cell differentiation over osteogenesis [4].  
 
Conclusion 
 
We successfully conjugated VEGF to PLGA nanofiber scaffold surface enabling bioactive 
VEGF releasing for 30 days. The angiogenic differentiation capacity of MSCs from both rat 
and human species have been enhanced significantly when culturing on the NF-VEGF 
scaffolds. The further enhancement, i.e. synergetic effect has been achieved when co-
culturing the MSCs with HUVECs on the NF-VEGF scaffolds. The proliferation and 
osteogenic differentiation level of MSCs when culturing with HUVECs on NF-VEGF 
scaffolds showed a species dependent response. Specially, the osteogenic differentiation of 
rMSCs was greatly enhanced by co-culturing with HUVECs and on NF-VEGF scaffolds, 
whilst hMSCs co-culturing with HUVECs or culturing on NF-VEGF scaffolds including 
mono-culture inhibited the osteogenesis of hMSCs. Thus, this study demonstrates that VEGF 
immobilization and HUVECs co-culturing are good strategies for vascularization in bone 
tissue engineering. However, the species dependent property of MSCs should also be 
considered when the application was different. 
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Figure Captions 
Figure 1 Schematic diagram of PLGA nanofibers modification process. Ammonia plasma 
treatment was done to introduce amine group to PLGA NF, and then heparin was 
grafted through crosslinker of EDC/NHS, finally, VEGF was covalently banded to 
NF-Heparin surface. 
 
Figure 2 A: SEM image of PLGA NF, inserted: distribution of fibers diameters (588.89 ± 
110.28 nm); B: The amount of heparin conjugation was quantified by Toluidine 
Blue assay; C: VEGF releasing from different surface (NF, NF-NH2, and NF-
Heparin) quantified by ELISA assay; D: Surface wettability tested by water contact 
angle, inserted images: water droplet on films. E-G: Immunofluorescence images of 
NF (E), NF-NH2 (F), and NF-Heparin (G) to show the VEGF modification. H: 
ELISA result to show the quantified VEGF modification. 
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Figure 3. Live & Dead staining of rMSCs cultured on NF (A1-A4), NF-NH2 (B1-B4), NF-
Heparin (C1-C4), and NF-VEGF (D1-D4) at day 5. A1-D1: bright field images; 
A2-D2: live cells (green); A3-D3: dead cells (red); A4-D4: merged. Scale bar: 200 
μm 
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Figure 4. A-C: Cell morphology observed by microscopy at day 3 of passage 2 (A: rMSCs, 
B: hMSCs, C: HUVECs); D-E: r/hMSCs proliferation with and without HUVECs 
seeded on PLGA NF and NF-VEGF surfaces (D: CCK-8 results of rMSCs/rMIX, 
E: CCK-8 results of hMSCs/hMIX). 
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Figure 5. Alizarin Red S staining results observed by microscopy at day 28 to show the 
osteogenic of rMSCs cultured on PLGA NF (A), NF-VEGF (B), and rMIX cultured 
on NF (C) and NF-VEGF (D). A1-D1: Black-white images of A-D processed using 
Image J software. E: The graph shows the area of ARS positive regions for the 
different study groups. (#: P>0.05, *P<0.05). Scale bar: 400 μm 
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Figure 6. Alizarin Red S staining results observed by microscopy at day 28 to show the 
osteogenic of hMSCs cultured on PLGA NF (A), NF-VEGF (B), and hMIX 
cultured on NF (C) and NF-VEGF (D). A1-D1: Black-white images of A-D 
processed using Image J software. E: The graph shows the area of ARS positive 
regions for the different study groups. (*P<0.05). Scale bar: 400 μm  
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Figure 7. CD31 immunofluorescence staining of rMSCs and rMIX cultured on PLGA NF and 
NF-VEGF to show the angiogenic of cells. A1-A3: rMSCs on NF; B1-B3: rMSCs 
on NF-VEGF; C1-C3: rMIX on NF; D1-D3: rMIX on NF-VEGF. (Red: CD31; 
Blue: nucleus) E: The CD31 staining area normalized by nucleus. (*P<0.05).  
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Figure 8 CD31 immunofluorescence staining of hMSCs and hMIX cultured on PLGA NF 
and NF-VEGF to show the angiogenic of cells. A1-A3: hMSCs on NF; B1-B3: 
hMSCs on NF-VEGF; C1-C3: hMIX on NF; D1-D3: hMIX on NF-VEGF. (Red: 
CD31; Blue: nucleus) E: The CD31 staining area normalized by nucleus. (#: 
P>0.05, *P<0.05). 
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